Piper Sandler raised the firm’s price target on Amgen (AMGN) to $329 from $310 and keeps an Overweight rating on the shares. The firm notes the ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...

Shares of Amgen Inc. AMGN shed 1.42% to $293.54 Friday, on what proved to be an all-around dismal trading session for the ...

Amgen (NASDAQ: AMGN) will present at the 35th Annual Oppenheimer Healthcare Life Sciences Conference at 11:20 a.m. ET on Wednesday, Feb. 12, 2025. Narimon Honarpour, senior vice president of global ...

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

THOUSAND OAKS, Calif., Jan. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025, after ...

Three major drug companies — Merck, Eli Lilly and Amgen — sued to block the rule, in part on First Amendment grounds. The judge didn’t take a view on that question, though, instead ruling ...

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Amgen's market standing. Stay informed and make well-considered decisions with our ...

Amgen Inc. closed 18.42% short of its 52-week high of $346.85, which the company achieved on July 25th.